339
Participants
Start Date
August 31, 2010
Primary Completion Date
December 31, 2010
Study Completion Date
December 31, 2010
FLOVENT™ DISKUS™ 100 mcg BID
FLOVENT™ DISKUS™ 100 mcg, one inhalation twice daily (BID) from the DISKUS device from randomization through the end of study (week 16).
ADVAIR™ DISKUS™ 100/50 mcg BID
ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a 100 mcg fluticasone propionate and a 50 mcg salmeterol. One inhalation from the DISKUS device twice daily (BID) from randomization through end of study (week 16).
GSK Investigational Site, Collegeville
GSK Investigational Site, Norfolk
GSK Investigational Site, Asheville
GSK Investigational Site, Orangeburg
GSK Investigational Site, Summerville
GSK Investigational Site, Lawrenceville
GSK Investigational Site, Atlanta
GSK Investigational Site, Gainesville
GSK Investigational Site, St. Petersburg
GSK Investigational Site, Owensboro
GSK Investigational Site, Canton
GSK Investigational Site, Ypsilanti
GSK Investigational Site, Madison
GSK Investigational Site, Oklahoma City
GSK Investigational Site, Oklahoma City
GSK Investigational Site, Oklahoma City
GSK Investigational Site, Dallas
GSK Investigational Site, Waco
GSK Investigational Site, Houston
GSK Investigational Site, Boerne
GSK Investigational Site, San Antonio
GSK Investigational Site, El Paso
GSK Investigational Site, Colorado Springs
GSK Investigational Site, Murray
GSK Investigational Site, Tucson
GSK Investigational Site, Albuquerque
GSK Investigational Site, Long Beach
GSK Investigational Site, Granada Hills
GSK Investigational Site, San Diego
GSK Investigational Site, Riverside
GSK Investigational Site, Huntington Beach
GSK Investigational Site, Orange
GSK Investigational Site, Bakersfield
GSK Investigational Site, Fresno
GSK Investigational Site, Walnut Creek
GSK Investigational Site, Sacramento
GSK Investigational Site, Medford
GSK Investigational Site, Brick
Lead Sponsor
GlaxoSmithKline
INDUSTRY